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Key points 
Question: What is the clinical validity of the DSM-5 Attenuated Psychosis Syndrome? 
Finding: In this systematic review, the clinical validity of the DSM-5 Attenuated 
Psychosis Syndrome (DSM-5-APS) was tested against evidence-based validators 
(antecedent, concurrent and prognostic). DSM-5-APS has received substantial 
concurrent and prognostic validation, mostly from psychometric research in the field of 
the clinical high-risk state for psychosis, while precipitating and predisposing 
epidemiological factors, neurobiological research and treatments have been under-
investigated. 
Meaning: Although current evidence supports the potential clinical validity of the DSM-
5-APS, more research should address the epidemiological profile of this diagnostic 
category, its predisposing and precipitating risk factors, neurobiological correlates and 






Importance: Since the release of DSM-5 Attenuated Psychosis Syndrome (DSM-5-
APS) in 2013, several research studies have investigated its clinical validity. Although 
critical and narrative reviews have reviewed these progresses, no systematic review has 
comprehensively summarised the available evidence regarding the clinical validity of 
DSM-5-APS. 
Objective: This systematic review and meta-analysis provide state-of-the-art evidence 
on the clinical validity of DSM-5-APS. 
Data source: Web of Science database (Clarivate Analytics), Cochrane Central Register 
of Reviews, Ovid/PsychINFO, conference proceedings and trial registries. 
Study selection: A multistep literature search up to 16 June 2019 was conducted 
following PRISMA and MOOSE guidelines and PROSPERO protocol, to include studies 
with original data investigating individuals with a DSM-5 APS or comparable 
designations. 
Data extraction and synthesis: The results were summarised in tables and narratively 
synthesised against established evidence-based validators (antecedent, concurrent and 
prognostic). A quantitative meta-analysis was conducted to explore the risk of psychosis 
onset in individuals diagnosed with the DSM-5-APS. 
Main outcome(s) and measure(s): For the systematic review: antecedent, concurrent 
and prognostic validators. For the meta-analysis: cumulative risk of psychosis onset at 
6-month, 12-month, 24-month and 36-month. 
Results: The systematic review included 56 articles, which reported on 124 validators: 
15 antecedents, 55 concurrent and 54 prognostic. The epidemiological prevalence of the 
DSM-5-APS in the general non-help seeking young population is 0.3%; the prevalence 
of the DSM-5-APS is variable in clinical samples. The inter-rater reliability for DSM-5-
APS is comparable to that of other DSM-5 mental disorders and can be optimised by the 
use of specific psychometric instruments. The DSM-5-APS is associated with frequent 
depressive comorbid disorders, distress, suicidality and functional impairment. Across 
23 prospective cohort studies, the meta-analytical risk of psychosis onset was 11% at 6 
months, 15% at 12 months, 20% at 24 months and 23% at 36 months follow-up. 
Research into predisposing and precipitating epidemiological factors, neurobiological 
correlates and effective treatments for DSM-5-APS has been limited.	
Conclusions and relevance: Over the recent years the DSM-5-APS has received 
substantial concurrent and prognostic validation, although mostly driven by research into 
the clinical high-risk state for psychosis. Precipitating and predisposing factors, 
neurobiological correlates and effective treatments are undetermined.	
Key words: Psychosis, Attenuated Psychosis Syndrome; Attenuated Positive Symptom 
Syndrome; Schizophrenia; Prevention, Risk. 
INTRODUCTION: 
 
Six years ago, the DSM-5 introduced the Attenuated Psychosis Syndrome diagnosis1 
(DSM-5-APS) in the research appendix, Section III under “Conditions for further study”, 
at page 7831 (Table 1). However, the DSM-5-APS also appears in the main body of text 
(page 122), where it is featured with the official codable diagnosis (298.8) of “Other 
Specified Schizophrenia Spectrum Disorder and Other Psychotic Disorder”1 (eTable 1). 
The rationale for introducing the DSM-5-APS was grounded on clinical research 
evidence from the Clinical High Risk state for Psychosis (CHR-P)2, which has allowed 
preventive interventions to enter clinical practice3. Consequently, the diagnostic structure 
of the DSM-5-APS is based on a subset of CHR-P risk criteria (eIntroduction): Attenuated 
Positive Symptom Syndrome (APSS) risk criteria, as defined by the Structured Interview 
for Psychosis-Risk Syndromes (SIPS4, from the second version, dated 8th June 19985,6, 
Table 1), and -to a lesser extent- Attenuated Psychotic Symptoms (APS) criteria, as 
defined by the Comprehensive Assessment of At-Risk Mental States (CAARMS7; Table 
1).  
 
Although the APSS, APS and DSM-5-APS all measure attenuated psychotic symptoms, 
there are substantial operationalisation differences across them (Table 1). The APSS 
and APS are measured through semi-structured interviews (SIPS and CAARMS 
respectively) that require specific psychometric training; conversely, the DSM-5-APS is 
unstructured and measured clinically -as for any other standard psychiatric diagnosis-. 
Consequently, the inter-rater agreement is very high within the SIPS8 and CAARMS9 but 
lower for the DSM-5-APS10. The psychosis onset is also defined psychometrically under 
the APSS and APS but clinically in the DSM-5-APS. Another key difference is that while 
the DSM-5-APS requires symptoms to be sufficiently distressing and disabling for the 
patient to warrant clinical attention (criterion D), this is not strictly required by the APSS 
or APS. The APS operationalisation substantially differs from the DSM-5-APS with 
respect to frequency (criterion B) and onset (criterion C) of symptoms, requirements for 
differential diagnosis with other mental disorders (criterion E; the APS is 
transdiagnostic11), substance misuse (symptoms induced by alcohol and cannabis are 
included in the APS) and threshold of psychosis onset (criterion F; because of different 
operationalisations of BLIPS12,13).  
 
Since the agreement between the DSM-5-APS and the APS in help-seeking individuals 
is only moderate14, these two operationalisations are similar but not identical, and they 
cannot be interchangeably used, as much as the DSM-5 schizophrenia and the DSM-5 
schizophreniform disorder share similarities but are distinctive diagnostic categories. The 
APSS and DSM-5-APS are more similar: all patients with APSS are also meeting DSM-
5 APS criteria15-18 and most -albeit not all- patients with DSM5-APS meet APSS criteria 
(43/44)15. However, disability and distress (criterion D) are not strictly part of the APSS 
(Table 1); to overcome this discrepancy the SIPS version 5.6 (dated 30 May 2014, p.44) 
has introduced an additional question to additionally rate criterion D of the DSM-5-APS 
(Table 1). Therefore, the SIPSv5.6.-DSM-5-APS can be used to psychometrically rate 
the DSM-5-APS. 
 
This is the first systematic review, complemented by meta-analytical analyses, which 
comprehensively assesses the advancements in diagnosis and treatment specifically for 
DSM-5-APS or closely related operationalisations, as opposed to loosely focusing on 




The study (study protocol registered on PROSPERO (CRD42019139330) was 
conducted in accordance with Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA, eTable 2)19 and Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE, eTable 3) guidelines20. 
 
Search strategy and selection criteria 
A multi-step literature search was performed using the following keywords: (“Attenuated 
Psychosis Syndrome” OR “Attenuated Psychosis Symptoms Syndrome” OR “APS” OR 
“APSS”). First, Web of Science database (Clarivate Analytics) was searched, 
incorporating the Web of Science Core Collection, BIOSIS Citation Index, KCI-Korean 
Journal Database, MEDLINE, Russian Science Citation Index, and SciELO Citation 
Index, as well as Cochrane Central Register of Reviews, and Ovid/PsychINFO databases 
from inception, until 16 June 2019, in English. Second, data in relevant conference 
proceedings (Schizophrenia International Research Society, Early Intervention in Mental 
Health) and trial registries (https://clinicaltrials.gov) were searched. Third, the references 
of systematic reviews or meta-analyses that were retrieved were manually searched. 
Abstracts of articles identified that were not relevant were screened out. The remaining 
full-text articles were then assessed for inclusion eligibility against the inclusion and 
exclusion criteria. 
 
Condition and individuals being studied 
The inclusion criteria were: a) original studies, abstracts or conference proceedings with 
no restriction on the topic investigated; b) conducted in individuals meeting the DSM-5-
APS, APSS or SIPSv.5.6-DSM-5-APS criteria (Table 1, the rationale is detailed in the 
introduction); c) studies published in English. 
The exclusion criteria were: a) reviews, editorials or clinical cases; b) unpublished data; 
c) studies measuring attenuated psychotic symptoms outside the DSM-5-APS, APSS or 
SIPSv.5.6-DSM-5-APS criteria, such as those employing the Basel Screening Instrument 
for Psychosis (BSIP21) or Comprehensive Assessment of At-Risk Mental States 
(CAARMS7) (which are prognostically14 but not diagnostically comparable to the DSM-5-
APS); d) studies that do not report specific information on the APSS group alone but 
reported composite results including other CHR-P subgroups (e.g. BLIPS and Genetic 
Risk and Deterioration Syndrome, GRD). 
 
Outcome measures and data extraction 
Data were independently extracted by two researchers (GSP, AC) and discrepancies 
were resolved consulting a third senior academic (PFP). The variables extracted 
included: validator (antecedent, concurrent, prognostic -see below), author and year of 
publication, study type (original or abstract), study design (cross-sectional, prospective, 
retrospective, intervention or naturalistic), type of diagnostic assessment (clinical or 
psychometric -including the SIPS version-; face to face, chart review or telephone), 
diagnostic operationalisation (DSM-5-APS, APSS or SIPSv.5.6-DSM-5-APS), sample 
size, mean age and percent of females, quality assessment (see below) and key findings. 
 
Quality assessment 
Study quality was assessed using a modified version of the Newcastle-Ottawa Scale 
(NOS) for cross-sectional and cohort studies22,23 (eTable 4). 
 
Systematic review 
To systematically assess the validity of DSM-5-APS, the available evidence was 
structured in 3 main classes of potential validators adapted from Kendler et al24: 
1. antecedent validators (demographic factors, predisposing and precipitating risk 
factors); 
2. concurrent validators (diagnostic factors and diagnostic agreement, comorbidity, 
neurobiological and neurocognitive factors, symptom measures and functioning, 
baseline treatments); 
3. prognostic validators (overall prognostic accuracy, risk of psychosis onset, 
predictors of outcomes, response to treatments). 
 
Meta-analysis 
A quantitative meta-analysis was conducted to test the risk of psychosis onset in DSM-
5-APS or APSS or SIPSv5.6-DSM-5-APS (Table 1). The risk of psychosis onset was 
estimated as the proportion of individuals at-risk who developed psychotic disorders 
(psychosis onset was defined by the SIPS or ICD/DSM) at 6, 12, 24, 36 (or more) months 
of follow-up, updating a previous publication25. A secondary meta-analysis was 
conducted to address the proportion DSM-5-APS, APSS or SIPSv.5.6-DSM-5-APS 
individuals presenting with (DSM/ICD) comorbid mental disorders. For these meta-
analyses, additional inclusion criterion were non-overlapping samples and availability of 
at least 3 independent studies reporting on the same outcome. For pooling proportions 
in a meta-analysis of multiple studies metaprop package 2126 of Stata statistical software 
(StataCorp, version 14) was used. The 95% CIs were based on score procedures25,27. 
Since high heterogeneity was expected, random-effects meta-analyses were 
conducted28. Publication biases were assessed with the metafunnel 29 and with the Egger 
test30 in metabias31 functions of Stata; the trim and fill method was used to correct the 
estimates in the case of publication biases32. Heterogeneity among study point estimates 
was assessed using Q statistics. The proportion of the total variability in the effect size 
estimates was evaluated with the I2 index33. Meta-regressions were planned when there 





The literature search yielded 27852 citations, which were screened for eligibility; 56 
articles reporting on 124 validators were included in the systematic review (Figure 1): 15 
antecedent validators, 55 concurrent validators and 54 prognostic validators. 21 and 10 
of the 56 studies were used for the risk of psychosis and comorbid mental disorders meta-
analyses, respectively. 46 studies employed the APSS designation, 5 the DSM-5-APS, 5 
both APSS and DSM-5-APS (in 1 study17 the sample was mixed and in 4 studies16,24,25,26 
the sample met both criteria) and none acknowledge using the SIPSv5.6-APS-DSM5. 
The total sample size of the studies included ranged from 2134 to 210135 individuals; the 
DSM-5-APS/APSS sample size ranged from 436 to 68937 and the age of participants 
ranged from 14.638 to 24.814. There were 26 studies from the US, 16 from Europe, 11 





The epidemiological prevalence of the DSM-5-APS in the general non-help seeking 
young population is 0.3%36 (eTable 5a). The onset/worsening criterion C excluded 2.3% 
of the general population who felt distressed by attenuated psychotic symptoms36. The 
prevalence of the APSS is 1.3%39 in the general population and 3.5% in college 
students40. The prevalence of APSS in clinical samples was highly variable ranging from 
3.1%35 to 80%41; the effect of age on the prevalence of DSM-5-APS/APSS in help-
seeking samples was inconsistent38,41,42. 
Retrospectively, 44% of patients diagnosed with schizophrenia would have met DSM-5-
APS criteria in the past15. 
 
Predisposing and precipitating risk factors 
47.8% of APSS individuals reported having experienced at least one type of trauma 
(eTable 5b)43. Younger APSS individuals (15-18 years) have better social and role 
functioning scores, less depressive symptoms than the older individuals38. Social 




Diagnostic factors and diagnostic agreement 
Assessors agree with the gold standard on the presence or absence of DSM-5-APS 70% 
(kappa= 0.34), of the times44 (eTable 6a). Pre-screening tools have robust psychometric 
properties for recognising APSS45. The inter-rater reliability for DSM-5-APS (kappa= 
0.46) is comparable to that of other DSM-5 mental disorders10. As noted in the 
introduction, the diagnostic agreement between the DSM-5-APS and the CAARMS 
12/2006 is only moderate (kappa= 0.59)14. 
 
Comorbidity 
Despite criterion E, about half (49%) of DSM-5-APS/APSS individuals presented with 
comorbid depressive disorders, 22% with bipolar disorder, 38% with anxiety disorders, 
9% with generalised anxiety disorder, 13% with obsessive-compulsive disorder, 20% 
with substance use disorders, 13% with cannabis abuse, 7% with alcohol abuse and 
22% with social phobia (meta-analytical results are reported in eTable 7-8). Other 
comorbid disorders that were not meta-analysed because there were less than 3 studies 
included attention deficit hyperactivity disorder46,47, oppositional defiant disorders17, 
conduct disorders17,38 and posttraumatic stress disorder (eTable 6b)42. Personality 
disorder traits were also frequent (57.1%)17, in particular schizotypal personality 
disorders (rates varied between 17.0%38 and 67.8%18) and borderline personality traits 
(42.9%17). Lifetime suicidality was more frequent in DSM-5-APS/APSS than non-DSM-
5-APS/APSS help-seeking individuals41,42: about 26.3%48-38.9%17 of the DSM-5-
APS/APSS population suffered at least one lifetime suicide attempt and suicidal ideation 
reached 77.8%17. The APSS designation was also associated with an increased risk of 
violence49. 
 
Neurobiological and neurocognitive factors 
Neurocognition47,50 (particularly vigilance and processing speed51), social cognition50 and 
metacognition47 (which related to self-disturbances46) were impaired in APSS subjects 
compared to controls (eTable 6c). Olfactory deficits in APSS individuals were associated 
with the severity of negative symptoms34. APSS individuals displayed enhanced fronto-
temporal functional brain connectivity52 and reduced mismatch negativity compared to 
controls53. 
 
Symptom measures and functioning 
Compared to other help-seeking samples, DSM-5-APS/APSS individuals were more 
severely ill17,41, depressed17, distressed35 and with a poorer functioning17,41 (eTable 6d). 
The severity of attenuated psychotic (positive, negative, disorganised and general) 
symptoms was significantly higher in APSS than non-APSS help-seeking individuals41,42; 
attenuated psychotic symptoms were also associated with obsessive-compulsive traits, 
interpersonal sensitivity and depression40. The most frequent unusual thought contents 
were being perplexed by reality and having overvalued beliefs54. The most frequent 
perceptual abnormalities were simple auditory43,54 (typically hearing their own voice with 
a negative content54) or simple visual43; tactile, olfactory or complex perceptual 
abnormalities were more infrequent. The severity of perceptual abnormalities was also 
lower in males compared to females43 and in those with simple compared to complex 
perceptual abnormalities43. The presence of violence content in attenuated psychotic 
symptoms was associated with increased anxiety, negative beliefs towards self and 
others and bullying55. 
 
Baseline treatments 
Baseline treatment exposure was: 5.5% - 57.1 % for antipsychotic medication16-18,53,56-62 
(mostly atypicals53,56), 0.0%-38.1 for antidepressants16-18,58-63 and 4.0%-20.8% for a 
combination of both16,18,41,60-62,64; 4.3%-33.3% for mood stabilisers17,58, 9.8%-14.3% for 





Overall prognostic accuracy 
There was only one study reporting on DSM-5-APS prognostic accuracy which resulted 
acceptable (AUC=0.76) at 24 months and comparable to that of the CAARMS14; those 
meeting DSM-5-APS criteria had a 5-fold probability of transitioning to psychosis 
compared to those high-risk individuals not meeting DSM-5-APS criteria (eTable 9)14. 
 
Risk of psychosis onset 
23 independent studies (1 in DSM-5-APS and 22 in APSS) reported risk of psychosis 
onset at follow-up, with an overall sample size of up to 2376 participants. The meta-
analytical psychosis risk was 11% at six months, 15% at 12 months, 20% at 24 months 
and 23% at 36 months follow-up (Figure 2, Table 2 and eTables 10-13). There were 
publication biases at 12-month and 24-month that were corrected with the trim and fill 
method (Table 3 and eTables 14-17). Meta-regressions did not show any effect of age, 
gender, publication year and study quality (eTable 18). In the only study employing DSM-
5-APS, there was a 28% risk of psychosis at 21-month14. 
 
Predictors of outcomes 
Mean age at the time of psychosis onset was 20.3 years for males and 23.5 years for 
females16, with a transition time of 234 days65 (eTable 9b). Of those who developed 
psychosis, 64.8% received a diagnosis of DSM schizophrenia61. 85.1% of individuals 
reached psychotic intensity on unusual thought content, 43.3% on suspicious ideas, 
13.4% on grandiose ideas and 46.3% on perceptual abnormalities65. Psychosis onset 
was characterised by the presence of Asian or Pacific Islander race16, and the 
emergence of new symptoms65 along with more severe and persisting 
positive/negative/general16,18,61 symptoms, and lower subjective well-being56,66. 
Attenuated odd ideas16, thought disorder16, unusual thought content59,61 and auditory 
perceptual abnormalities60 were associated with a higher risk for psychosis, while visual 
perceptual abnormalities with a lower risk60. Speech features64, in particular disorganized 
communication58,59 were also associated with an increased risk of psychosis, as well as 
a decline in social functioning58,59. Verbal memory deficits51,59,58, verbal fluency59, 
processing speed51,59 and composite cognitive measures51 were associated with an 
increased risk of psychosis. Similarly, abnormalities in emotional processing45,67, motor 
dysfunction62, olfactory dysfunction34 and mismatch negativity53 were associated with an 
increased risk of psychosis. Schizotypal personality disorder was not associated with 
increased risk of psychosis18 but axis II disorders along with familial psychiatric history, 
tobacco use, number of hospitalisations, history of trauma were associated with suicide 
attempts48. None of these predictors was externally replicated. 
 
Response to treatment 
Naturalistic studies found that 25.5% of individuals received antidepressants for an 
average of 3-month with no improvement in negative symptoms or social functioning63 
and that 48% of individuals showed little improvement in their symptoms, after one year, 
despite being treated with supportive therapy and/or psychotropic medication56 (eTable 
9d). The only available randomised controlled trial found no significant differences in risk 
of psychosis onset, improvement of severity of symptoms or functioning between 
cognitive behavioural therapy and supportive therapy68. 
 
Quality assessment 
The NOS scores ranged from 3 to 8 (eTables 19-20). 
 
DISCUSSION 
While there are many meta-analyses on CHR-P in the literature, to our knowledge, this 
is the first systematic review that specifically addressed the clinical validity of DSM-5 
APS across 56 studies and 124 validators. Most of the evidence reviewed focused on 
concurrent and prognostic validators in APSS individuals, while antecedent factors were 
rarely investigated. 
 
The systematic review of antecedent validators identified only a few records. The 
prevalence of DSM-5-APS is 0.3% in the general population36, 3.5% in college students40 
and highly variable in clinical samples14,41,42. The latter point reflects the significant 
sampling biases that affect the CHR-P/APSS paradigm69-73. There is an overall paucity 
of robust epidemiological research addressing the specific risk or protective factors that 
may exert a predisposing or precipitating role in the DSM-5-APS/APSS. While recent 
reviews have indicated that psychosis onset is largely driven by non-purely genetic risk 
factors74,75 22, it is not clear how these factors accumulate in DSM-5-APS/APSS samples. 
A further public health limitation is that only half of individuals would report a DSM-5-
APS like state preceding their first episode of schizophrenia15, questioning the 
universality of this syndrome as pre-psychotic stage. Other retrospective cohort studies 
have confirmed a reasonably large subgroup (30%) of first episode of psychosis patients 
for whom there is no evidence of meeting prior CHR-P criteria for any identifiable length 
of time76,77. The possibility that non-psychotic risk syndromes could precede the first 
onset of psychosis was recently summarised at meta-analytical level78. 
 
The systematic review identified more concurrent validators. Inter-rater reliability for 
DSM-5-APS is comparable to that of other DSM-5 mental disorders, although the 
confidence intervals of the field test were very large10. Noticeably, the reliability of the 
DSM-5-APS can be optimised if the SIPSv5.6 is being used. Unfortunately, to date, only 
a few studies have acknowledged using this specific SIPS version. Furthermore, despite 
the criterion E requiring a differential diagnosis, half of the individuals meeting DSM-5-
APS/APSS had comorbid major depressive disorders (table 2). This is in line with 
phenomenological accounts highlighting the role of mood dysregulation during the 
phases that precede the psychosis onset79 and supporting the notion that psychosis may 
arise from multiple psychopathological spectra80. Given that psychosis onset can occur 
from non-psychotic risk syndromes, the removal of this criterion may improve both its 
prognostic performance and transdiagnostic value11,14,81. Symptomatically, the DSM-5-
APS/APSS individuals were more severely ill, more depressed and with a poorer 
functioning than other help-seeking samples not meeting the DSM-5-APS/APSS, with a 
duration of untreated attenuated psychotic symptoms was around 710 days25. 
Attenuated positive psychotic symptoms more frequently included derealisation, 
overvalued beliefs and simple auditory abnormalities43,54 and the presence of violence 
content was associated with high distress55. This supports the notion that DSM-5-APS 
indexes a clinical syndrome which is disabling per se and independent from the 
outcomes23,81. In fact, the vast majority of DSM-5-APS/APSS individuals had suicidal 
ideation and up to one-third of them attempted suicide17. At baseline, up to 57% of 
individuals received antipsychotic medication17, 38% antidepressants17 and 33% mood 
stabilisers17, corroborating the polymorbid distressing nature of this syndrome. 
Neurocognitive47,50,51, social cognitive50 and metacognitive47 dysfunction, although not 
diagnostically required, are also frequent, while neurobiological research into DSM-5-
APS/APSS is too limited to draw reliable conclusions. 
 
The systematic review of prognostic validators confirmed that DSM-5 APS prognostic 
accuracy is acceptable (AUC=0.76) at 24 months and comparable to the CAARMS14. 
Individuals meeting DSM-5 APS/APSS criteria had a 5-fold probability of transitioning to 
psychosis compared to those high-risk individuals not meeting these criteria, with a 23% 
risk of psychosis at 36 months follow-up (Figure 2, Table 2 and eTable 13). The only 
study employing DSM-5-APS criteria reported a 28% risk of psychosis onset at 21-
month14. Of those who converted, around 2/3 received a diagnosis of schizophrenia61. 
These findings indicate a substantial risk of progression to psychosis, on top of the 
baseline distressing clinical profile of the syndrome. However, predicting clinical 
outcomes in this population is currently hampered by the lack of externally validated 
prognostic models82; available models developed with stepwise approaches58 did not 
replicate well in external samples59. There was very limited evidence relating to effective 
treatments for DSM-5-APS/APSS, in line with the current state of knowledge of the CHR-
P field83. Only one randomised controlled trial compared cognitive behavioural therapy 
and supportive therapy without finding differences between them68. Some trials are 
ongoing and are addressing the potential effects of treatments on clinical remission and 
functional outcomes81 beyond psychosis onset84. 
 
The potential clinical validity of DSM-5-APS is further confirmed by surveys conducted 
in the general public and health care professionals (eTable 21). Most practitioners 
consider DSM-5-APS to constitute a mental disorder98 in which medication, family 
involvement and cognitive coping skills can be helpful99. Importantly, in none of these 
surveys involving the general public, health care professionals100, undergraduates101 and 
college students102, the levels of stigma associated with the DSM-5-APS /APSS were 
perceived higher than other mental disorders or than other psychotic-like 
experiences100,101. 
 
The main limitation of this review is the scarce amount of evidence on precipitating and 
predisposing factors, neurobiology and preventive treatments. A further important 
limitation is that the vast majority of studies employed the APSS designation which does 
not exactly match the DSM-5-APS. For example, some studies measured APSS and 
considered them as DSM-5-APS without clarifying the SIPS version used17,34,37-43,45-
47,49,51-60,62-64,66-68,85-96 or whether the symptoms were distressing and disabling to the 
patient to warrant clinical attention42,97. Therefore, this review supports the clinical utility 
of the APSS and since the DSM-5 APS is most similar, it is supporting the DSM-5 APS 
clinical utility. Future studies are required to carefully avoid confusing CHR-P 
operationalisations with the DSM-5-APS category, by testing all the criteria A to F (Table 
1) upfront, either clinically or using the SIPSv.5.6-DSM-5-APS (Table 3). Accordingly, 
the text describing the DSM-5-APS should be revised for accuracy and consistency with 
the specific evidence presented here. Most importantly, the revision of the DSM-5-APS 
should carefully overcome the current misleading availability of different specifications 
across the main text and research appendix (eTable 1). Because of such inconsistency, 
individuals at risk of psychosis may be mislabelled under the rubric of “Other Specified 
Schizophrenia Spectrum and Other Psychotic Disorder”42. Furthermore, with few 




Current evidence supports the potential clinical validity of the DSM-5-APS. However, 
more research is required to clarify the epidemiological profile of this diagnosis, its 
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Diagnostic criteria     
Severity A. At least one of the following 
symptoms is present in attenuated 
form, with relatively intact reality 
testing, and is of sufficient severity or 
frequency to warrant clinical 
attention: 
1. Delusions 2. Hallucinations 3. 
Disorganised speech  
SOPS-positive symptom scales P1. 
unusual thought content, P2. 
suspiciousness, P3. grandiose ideas, 
P4. perceptual abnormalities, P5. 
disorganised communication, with 
at least one of these symptoms rated 
3, 4, or 5 indicating clinically 
significant disturbance below a 
psychotic level of intensity  
As for APSS CARMS-positive symptoms scales 
rated 3-5 (P1. unusual thought 
content, P2. non-bizarre ideas), 3-4 
(P3. perceptual abnormalities), 4-5 
(P4. disorganised speech) 
Frequency B. Symptom(s) must have been 
present at least once per week for the 
past month 
Symptoms ever been present at an 
average frequency of at least 
once/week over a month 
As for APSS Symptoms present from 1/month to 
2/week, >1 h per occasion, OR 3 to 
6/week, <1 h per occasion 
New onset and 
worsening 
C. Symptom(s) must have begun or 
worsened in the past year 
Begin within the past year, or any 
currently rate one or more scale 
points higher compared to 12 
months ago; rated only symptoms 
that occurred over the past month 
As for APSS Need to be present in the past 12 
months; rated the most severe in 
the past 12 months 
Distress/disability D. Symptom(s) is sufficiently 
distressing and disabling to the 
individual to warrant clinical 
attention 
Subjective qualifier not used to 
assign the designation 
Attenuated positive 
symptoms sufficiently 
distressing and disabling to 
the patient to warrant 
clinical attention 
Rated on a scale 0-100 but not 
used to assign the designation 
Differential diagnosis E. Symptom(s) is not better explained 
by another mental disorder, including 
a depressive or bipolar disorder with 
psychotic features, and is not 
attributable to the physiological 
effects of a substance or another 
medical condition 
Symptoms ever not been explained 
better by another DSM disorder 
As for APSS No requirement for differential 
diagnosis with other mental 
disorders 
Lack of lifetime 
psychotic disorder 
F. Criteria for any psychotic disorder 
have never been met 
Severity score of 6 on at least one of 
P1–P5 AND symptoms ever occur 
for at least 1h/day at an average 
frequency of four days/week over 
one month OR symptoms are 
seriously disorganising and 
dangerous (urgency criteria) 
As for APSS Severity score of 6 on at least one 
of P1, P2, P4 and/or 5–6 on P3 
AND frequency of at least 3 to 
6/week, > 1 h per occasion, or 
daily, <1 h per occasion AND 
symptoms present for longer than 
one week. Urgency criteria not 
considered. 
Substance misuse Assessed within criterion E Exclude if symptoms are strongly 
intertwined temporally with 
substance use episodes 
As for APSS Exclude if symptoms occur only 
during peak intoxication from 
hallucinogens, amphetamines and 
cocaine; included if due to 
cannabis or alcohol 
Antipsychotic 
treatments 
Not assessed Usually assessed and considered as 
an exclusion criterion 
As for APSS Usually assessed and considered as 
an exclusion criterion 
Functional decline No social/occupational dysfunction 
decline requirement 
No social/occupational dysfunction 
decline requirement 
As for APSS 30% drop in SOFAS score from 
premorbid level, sustained for a 
month, within the past 12mo OR 
SOFAS score <50 for the past 12 
months or more 
Assessment Unstructured clinical interview Semi-structured psychometric 
interview 
As for APSS Semi-structured psychometric 
interview 
Duration of the 
assessment 




Not required Required As for APSS Required 
*SOFAS: Social and Occupational Functioning Assessment Scale. 






































Records identified through 
database searching 






















Additional records identified 
through other sources 
(n = 40) 
Title and abstract screened for eligibility 
(n = 27862) 
Full-text articles assessed 
for eligibility 
(n = 275) 
Studies extracted for 
being potentially relevant 
to the topic                            
 (n= 61)  
Records excluded 
during title and 
abstract screening  
(n = 27587) 
Full-text articles 
excluded during full-
text screening  
(n= 214) 
 
Studies that did not 
meet our inclusion 
criteria because they 
were not conducted in 
patients  




Studies included in the 
qualitative systematic 
review (n=56); validators 
(124) 
 























































Follow up time 
 
 
Table 2 to Figure 2. Cumulative risk of psychosis onset in individuals with DSM 5-APS/APSS 
 
* all studies but one14 refer to APSS; a) 0.104, 95%CI 0.062-0.145 after the fill and trim method; b) 0.139, 
95%CI 0.097-0.182 after the fill and trim method. 








95%CI Q df I2 P 
6-month 12 824 0.11 0.08-0.14 20.77 11 47.04 0.04 
12-month 19 1292 0.15(a) 0.11-0.19 61.02 18 72.14 <0.01 
24-month 18 2212 0.2(b) 0.16-0.24 87.22 17 79.36 <0.01 
36-month 7 721 0.23 0.17-0.30 22.2 6 72.97 <0.01 
Table 3. Evidence-based reporting recommendations for future DSM-5-APS clinical 
research 
1 Test the specific DSM-5-APS criteria A to F upfront in a standard psychiatric 
clinical assessment  
2 Report the exact number of patients meeting the specific DSM-5-APS criteria A 
to F  
3 If CHR-P instruments are being used indicate their type and version and stratify 
the findings across APSS/APS, GRD and BLIPS/BIPS subgroups 
4 Preferably use the SIPSv.5.6 for the psychometric assessment of DSM-5-APS; 
ensure an appropriate training 
5 If both clinical DSM-5-APS and psychometric APSS/APS criteria are tested in 
the same patients, detail their concordance/discordance. 
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